Announced details
OTC drugs; thirst and dry throat associated with elevated blood glucose; diabetes
Relieves postprandial blood glucose elevation and thirst and dry throat associated with elevated blood glucose (quantitative effects: not disclosed)
Planned and marketed by ノーエチ薬品株式会社, and sold through retailers
ノーエチ薬品株式会社: Matsubara, Osaka Prefecture
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Keihi Powder [Granules] GS |
| Counterparty | Retailers (no specific company names disclosed) |
| Relationship with the Company | Planned and marketed by ノーエチ薬品株式会社, and sold through retailers |
| Launch date | On sale as of 16 September 2026; no specific launch date disclosed |
| Applicable area | OTC drugs; thirst and dry throat associated with elevated blood glucose; diabetes |
| Location | ノーエチ薬品株式会社: Matsubara, Osaka Prefecture |
| Quantitative Effects | Relieves postprandial blood glucose elevation and thirst and dry throat associated with elevated blood glucose (quantitative effects: not disclosed) |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the Group is expanding its business beyond dentistry into the development and manufacture of OTC drugs for general consumers. In addition, although mass production had previously been difficult, the Group reviewed its processes and achieved mass production.